Loading presentation...

Present Remotely

Send the link below via email or IM

Copy

Present to your audience

Start remote presentation

  • Invited audience members will follow you as you navigate and present
  • People invited to a presentation do not need a Prezi account
  • This link expires 10 minutes after you close the presentation
  • A maximum of 30 users can follow your presentation
  • Learn more about this feature in our knowledge base article

Do you really want to delete this prezi?

Neither you, nor the coeditors you shared it with will be able to recover it again.

DeleteCancel

Make your likes visible on Facebook?

Connect your Facebook account to Prezi and let your likes appear on your timeline.
You can change this under Settings & Account at any time.

No, thanks

Copy of Bristol Myers Squibb FINAL

No description
by

Ordos Zhao

on 18 March 2014

Comments (0)

Please log in to add your comment.

Report abuse

Transcript of Copy of Bristol Myers Squibb FINAL

Ratio Analysis
Introduction
Background
by Matida, Rebecca, Joseph, Peter, Oliver and Ordos
to discover, develop and deliver innovative medicines and help patients prevail over serious diseases.
MISSION STATEMENT
SWOT
Strengths
Good financial and R&D performance
BMS delivers new medicines regularly
Strong brand name
Good corporate strategy
Specialisation
patent rights
Weaknesses
Strategy only focus on biologic drugs, not diversify into producing animal&generic drugs
Expiring patent
Opportunities
Opportunities to expand
Opportunities to diversify
There are still diseases that do not have cure
Threats
Stiff competition
Loss of patent rights for Plavix
Risk of counterfeit drugs in the market
Key Facts
First formed by Edwards Robinson Squibb, a US navy doctor in 1819-1900
In 1989, Bristol-Myers merged with Squibb creating a global leader in the health care industry
The merger created BMS, as the world's one of the largest pharmaceutical enterprise
Today, BMS has facilities worldwide, including in Belgium, Brazil, China, England, France, Ireland, Italy, Japan, Mexico Puerto Rico and the United States
Outlook
Source:
BMS official website
Photo:
Alamy,
the telegraph

Performance
$4.81bn
$5.01bn
2010
1st quarter 2011
by December 2010
New skin cancer drug
Bright Prospect
Bristol-Myers Squibb annual report 2010

Bristol-Myers Squibb annual report 2011

http://www.bms.com

http://www.stock-analysis-on.net/NYSE/Company/Bristol-Myers-Squibb-Co/Valuation/Ratios

Gail J.Robin., 2011.
Bristol-Myers Squibb--2011
. Baker College
References List:
Thank you for Listening!
4%
e.g. No.1 company Pfizer 8%
Internal Analysis
Resources, competences and competitive advantage
External Analysis
Porter's 5 forces
Threat of new entrants
(Low)
Threat of substitute
Bargaining power of buyers
Bargaining power of suppliers
Competition/ Rivalry
(High)
(Medium)
(Low)
(Low)
PESTEL
Strategy formulation
Ansoff's Matrix

1. Human Resources
2. Brand Name
3. Financial Stability
4. Patent Protection
5. Technological Advancement
6. World Spread infrastructure
Resources
Are they valuable?

Yes

1. Human Resources
2. Brand Name
3. Financial Stability
4. Patent Protection
5. Technological Advancement
6. World Spread infrastructure
Are they rare?
Yes

1. Human Resources
2. Brand Name
3. Financial Stability
4. Patent Protection
5. Technological Advancement
6. World Spread infrastructure
No
Yes
Is it imitable?
1. Brand Name
2. Human Resources
3. Technological Advancement
1. Financial Stability
2. Patent Protection
3. World wide Infrastructure
Is the BMS able to exploit these resources?
Yes
Yes
Competitive
Advantages
Competences
1. Research and Development
2. Innovative Ability
3. Financial Stability
4. Advanced Technology
5. Fast Mover Company
6. Acquiring Market Share
7. Efficient use of Human Resources
Are they valuable?
Yes
Are they rare?
No
Yes
1. Research and Development
2. Fast Mover Company
3. Efficient use of Human Resources
1. Research and Development
2. Innovative Ability
3. Financial Stability
4. Advanced Technology
5. Fast Mover Company
6. Acquiring Market Share
7. Efficient use of Human Resources

1. Innovative Ability
2. Financial Stability
3. Advanced Technology
4. Acquiring Market Share

Are they imitable?
Yes
No
1. Research and Development
2. Fast Mover Company
3. Efficient use of Human Resources

1. Innovative Ability
2. Financial Stability
3. Advanced Technology
4. Acquiring Market Share

1. Research and Development
2. Fast Mover Company
3. Efficient use of Human Resources
Permanent Competitive Advantages
Temporary Competitive Advantages

1. Innovative Ability
2. Financial Stability
3. Advanced Technology
4. Acquiring Market Share

Competitive Advantage
VRIO model
Source:
Bristol-Myers Squibb
annual report 2010
Source:
Bristol-Myers Squibb
annual report 2010
Source:
Bristol-Myers Squibb
annual report 2010
BMS VS industry leaders (April 2011)
Full transcript